Tilray (TLRY) shares closed nearly 60% higher on Sept. 29 after President Donald Trump promoted cannabidiol’s (CBD) potential to “revolutionize senior healthcare” in a video posted on Truth Social. In his social media post, the U.S. president also said the hemp-derived medicinal compound could generate substantial – as much as $64 billion annually – in medical cost savings as well. More News from Barchart Following Monday’s rally, Tilray stock hit a new 52-week high of $1.86. www.barchart.com Why Trum ...

Stock Market Overview - U.S. stocks advanced, with the Nasdaq rising 107 points (0.48%) to 22,591.15, S&P 500 up 0.26% to 6,661.21, and Dow Jones increasing 0.15% to 46,316.07 [1] Wolfspeed Inc. (NYSE: WOLF) - Wolfspeed's stock surged by 1,726.45%, closing at $22.10, with an intraday high of $22.10 and a low of $8.05; it reached a 52-week high of $22.10 and a low of $0.39 [2] - The surge followed the announcement of a reorganization plan under Chapter 11 bankruptcy, which will reduce debt by 70% and cut interest payments by 60% [3] Tilray Brands, Inc. (NASDAQ: TLRY) - Tilray's shares increased by 60.87%, closing at $1.85, with a high of $1.86 and a low of $1.34; the stock's 52-week high and low are $1.86 and $0.35, respectively [4] Robinhood Markets Inc. (NASDAQ: HOOD) - Robinhood's stock rose 12.27%, closing at $136.72, with an intraday high of $136.84 and a low of $123.78; it achieved a new all-time high of $136.84, with a 52-week low of $22.05 [5][6] - The rally followed the CEO's announcement that event contracts on the platform topped four billion, with half traded in the third quarter alone, and a strong August report showing assets surged 112% year-over-year to $304 billion [6] Etsy - Etsy's shares climbed 15.83%, closing at $74.34, with a high of $75.77 and a low of $63.64; the stock's 52-week high and low are $75.77 and $40.05, respectively [6] - The increase was driven by OpenAI's unveiling of the "Buy it in ChatGPT" feature, allowing users to purchase directly from Etsy sellers [7] MoonLake Immunotherapeutics (NASDAQ: MLTX) - MoonLake's stock plummeted by 89.93%, closing at $6.24, with a high of $7.14 and a low of $5.95; the stock's 52-week high is $62.75, with a low of $5.95 [8] - The decline occurred despite positive results from MoonLake's Phase 3 VELA trial, which showed statistically significant HiSCR75 responses in patients with moderate to severe hidradenitis suppurativa [8]

Market Performance - Market indexes experienced gains, with the Dow up +68 points, S&P 500 gaining +17 points, and Nasdaq increasing +107 points, while the Russell 2000 rose +2 points [2] - The market was influenced by a government shutdown threat and OPEC+'s decision to raise oil production by 137K barrels per day, leading to a -3.8% drop in WTI prices and a -2.5% decline in Exxon Mobil and BP stocks [1] Housing Market - Pending Home Sales rose by +4.0% in August, surpassing expectations and reversing a previous downward trend, aided by slightly easing mortgage rates [3] - Newly-built homes also saw an increase, with homebuilder stocks like Lennar, Pulte Home, and KB Home rising more than +1% due to pent-up demand [4] Cannabis Industry - The Trump administration is considering reclassifying cannabis from Schedule I to Schedule III, which could have significant implications for the industry, resulting in a +60% increase in Tilray's stock price [5] Economic Data Expectations - Upcoming economic data includes Case-Shiller Home Prices, Chicago Business Barometer, and Consumer Confidence, with expectations for slight increases and a narrowing in Consumer Confidence to 95.8 [6] - The Job Openings and Labor Turnover Survey (JOLTS) is expected to show a decrease in job openings to 7.1 million, the lowest since September 2024 [7] Company Earnings - Nike is set to report fiscal Q1 earnings, with expectations of a -60% year-over-year earnings decline and -4.95% revenue drop, despite having outperformed earnings expectations for eight consecutive quarters [8][9]

Shares of cannabis and CBD-related companies surged on Monday after US President Donald Trump posted on Truth Social that hemp-derived cannabidiol (CBD), especially in senior healthcare,  “could revolutionize” treatment by reducing disease progression and providing an alternative to prescription drugs.He further reiterated his administration is exploring reclassifying marijuana under federal law, a change that could ease criminal penalties and open broader market access.The market reacted strongly: Tilray B ...

U.S. equity markets presented a mixed but generally positive picture on Monday, September 29, 2025, as investors navigated a landscape dominated by a looming government shutdown, a rebound in technology stocks, and key corporate announcements. Major indexes largely closed higher, clawing back some losses from the previous week, even as the specter of a federal funding lapse cast a shadow over Washington.Today's Market Performance RecapThe trading day saw a rebound across the board for the primary U.S. stock ...

Cannabis stocks are on a high after Donald Trump shared a video on Sunday promoting cannabis use for seniors and Medicaid coverage of CBD products.The nearly three-minute-long video, posted on the president’s Truth Social platform, touts the usage of hemp-derived CBD as a “gamechanger” that is a pain and stress reliever for seniors.Stocks for cannabis companies, including Canopy Growth, Tilray and Cronos Group jumped Monday when stocks opened for the week. MSOS, an AdvisorShares Cannabis exchange-traded fun ...

Industry Overview - The cannabis industry is experiencing a positive shift following President Trump's endorsement of cannabidiol (CBD) for senior healthcare, leading to a rally in cannabis shares [1][2] - The U.S.-listed shares of Canadian cannabis companies are seeing significant gains, indicating a strong market reaction [1] Political Influence - Trump's statement on CBD as a potential alternative to traditional prescription drugs may provide momentum for the cannabis industry, which has faced strict regulations [2][3] - The possibility of reclassifying marijuana under federal law could alleviate operational and tax challenges for cannabis businesses, although it would not equate to full legalization [2][3] Market Performance - Analysts highlight that political backing, even if symbolic, is crucial for an industry struggling with regulatory hurdles [3] - The global cannabis market is projected to reach a value of $444.34 billion by 2030, showcasing its high growth potential despite volatility [4] Stock Performance - Notable stock performance includes: - Tilray Brands (TLRY) up 41.3% - Aurora Cannabis (ACB) up 23.6% - Canopy Growth (CGC) up 15.7% - Green Thumb Industries (GTBIF) up 15.7% - Curaleaf Holdings (CURLF) up 20% - Trulieve Cannabis (TCNNF) up 12.7% [5]

And a post last night on Truth Social, President Trump shared a video highlighting the health benefits of hemp hemp derived cannabid oil or CBD. Now, Tillray, Canopy Growth, Aurora, all jumping double digits. The video said it could quote, "Revolutionize senior health care, serving as a alternative to costly prescription drugs." Of course, another area of the president's focus.Now, this isn't Trump's first move in cannabis, though. Back in the 2018 Farm Bill, hemp derived products like CBD were legalized. A ...

Company Earnings - Carnival (NYSE: CCL) reported third-quarter earnings of $1.43 per share, exceeding the analyst consensus estimate of $1.32 per share [2] - The company also reported quarterly sales of $8.153 billion, surpassing the analyst consensus estimate of $8.101 billion [2] Stock Movements - Tilray Brands, Inc. (NASDAQ: TLRY) shares increased by 40% to $1.6050 following a video from President Donald Trump promoting cannabis health benefits [8] - Merus N.V. (NASDAQ: MRUS) shares surged 36% to $93.93 after Genmab agreed to acquire the company for $97 per share [8] - Better Home & Finance Holding Company (NASDAQ: BETR) shares rose 17% to $62.23 after announcing a $75 million at-the-market offering for Class A shares [8] - KALA BIO, Inc. (NASDAQ: KALA) shares plummeted 89% to $2.15 after failing to meet primary endpoints in a clinical trial [8] - MoonLake Immunotherapeutics (NASDAQ: MLTX) shares fell 89% to $6.69 due to a failed trial [8] - IO Biotech, Inc. (NASDAQ: IOBT) shares dropped 78% to $0.3501 following an update after a pre-BLA meeting with the FDA [8] Economic Indicators - U.S. pending home sales surged by 4% in August, marking the sharpest gain in five months, compared to a 0.4% decline in the previous month [10] - The Dallas Fed's general business activity index for Texas manufacturing declined to -8.7 in September from -1.7 in the previous month [10]

Core Viewpoint - Cannabis stocks experienced significant gains following President Donald Trump's promotion of a video advocating for the inclusion of cannabidiol (CBD) under Medicare coverage [1][6]. Group 1: Stock Performance - Tilray Brands surged nearly 20% and was up 36% after market open [1]. - Canopy Growth jumped about 20%, while Cronos Group rose 13% [1]. - Aurora Cannabis climbed 13.3%, and Trulieve Cannabis spiked almost 20% [1]. - Green Thumb Industries, Curaleaf Holdings, and Innovative Industrial Properties also saw considerable share price increases [3]. Group 2: Video Promotion and Content - The video produced by The Commonwealth Project features Trump and a narrator advocating for wider access to CBD for seniors [6][9]. - The narrator claims that hemp-derived CBD can significantly improve the quality of life for older adults [7][10]. - The video suggests that CBD can help restore the endocannabinoid system and assist with pain, sleep, and stress [10]. Group 3: Regulatory Context - Trump previously indicated he was considering reclassifying marijuana as a less dangerous substance, although no action has been taken yet [8]. - The timing of the video promotion coincides with Congress deliberating on tightening hemp regulations, with some Republicans advocating for stricter limits on CBD products containing trace amounts of THC [8].